Zydus Cadila and Taiwan-based pharmaceutical company TLC signed a pact on Wednesday to commercialize liposomal amphotericin B, a key drug used in the treatment of mucormycosis (black mold), in India.
The companies announced that they have signed an agreement to commercialize AmphoTLC (Amphotericin B Liposome For Injection 50 mg) in India, Zydus Cadila said in a statement.
“Given an acute shortage of drugs to treat mucormycosis in India, we are making this critical drug available in India immediately,” said Sharvil Patel, General Manager of Cadila Healthcare. The need of the hour is to combat this life-threatening infection with safe and effective therapy, he added.
The Central Drugs Standard Control Organization has approved DC’s New Drug Use (NDA) for Amphotericin B Liposome For Injection of 50 mg for Immediate Entry as Approved Use and Indication, Zydus Cadila said.
With black fungus cases rising in India in recent days, AmphoTLC will address the acute liposomal amphotericin B deficiency in the country, he added. Mucormycosis is a serious fungal infection, also known as black fungus, and COVID-19-associated mucormycosis is life-threatening, the statement said.
AmphoTLC is a liposomal amphotericin B injection indicated for severe systemic fungal infections such as mucormycosis. The shares of Cadila Healthcare, the publicly traded company of the Zydus Group, traded on BSE at 626.45 rupees per share, an increase of 0.64 percent from the previous close. PTI ACT